Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis
Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis
复制标题
乐伐替尼与索拉非尼治疗不可切除的肝细胞癌：成本效益分析
DOI：
10.2217/cer-2020-0041
复制
发表时间：
2020-06-01
影响因子：
2.1
通讯作者：
Liu, Maobai
中科院分区：
文献类型：
--
作者：
Cai, Hongfu;Zhang, Longfeng;Liu, Maobai
目的：研究乐伐替尼和索拉非尼治疗中国未切除肝细胞癌患者的成本-效果。材料和方法：应用马尔可夫模型对肝癌患者的直接医疗费用和质量调整生命年（QALY）进行了模拟。临床数据来源于在中国人群中进行的III期随机临床试验。结果：索拉非尼治疗导致1.794个Qs，成本为43，780.73美元。乐伐替尼治疗导致患者体重增加2.916个QTLs
Aim: To investigate the cost-effectiveness of lenvatinib and sorafenib in the treatment of patients with nonresected hepatocellular carcinoma in China. Materials & methods: Markov model was used to simulate the direct medical cost and quality-adjusted life years (QALY) of patients with hepatocellular carcinoma. Clinical data were derived from the Phase 3 randomized clinical trial in a Chinese population. Results: Sorafenib treatment resulted in 1.794 QALYs at a cost of $43,780.73. Lenvatinib treatment resulted in 2.916 QALYs for patients weighing